Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Akebia Therapeutics (AKBA) Misses Q1 EPS by 6c
May 9, 2022 4:22 PM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.35), $0.06 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $61.7 million versus the consensus estimate of $44.22 million.
GUIDANCE:
Akebia Therapeutics sees FY2022 revenue of $165-170 million.
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
... More